{"id":"W4401539643","doi":"10.1016/j.lungcan.2024.107928","title":"Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma","year":2024,"lang":"id","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Foundation Medicine; Sanofi Genzyme; Genentech; Regeneron Pharmaceuticals; National Institutes of Health; Jazz Pharmaceuticals; European School of Oncology; AstraZeneca; Novocure; Invitae; Silverback Therapeutics; Verily Life Sciences; Boston Pharmaceuticals; Takeda Oncology; Mirati Therapeutics; Chugai Pharmaceutical; Lung Cancer Research Foundation; Revolution Medicines; International Association for the Study of Lung Cancer; U.S. Department of Defense; Sanofi; Bristol-Myers Squibb; Pfizer; University of Miami; National Cancer Institute; Bayer; Mesothelioma Applied Research Foundation","keywords":"Pembrolizumab; Medicine; Randomized controlled trial; Mesothelioma; Internal medicine; Oncology; Pathology; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003175392,0.0003875944,0.001296286,0.0002429783,0.00009131079,0.00006154842,0.0001209568,0.0001355587,0.001221258],"category_scores_gemma":[0.0001182548,0.0003150805,0.0004307619,0.0002698662,0.0002871711,0.0001045756,0.00007487352,0.0001366028,0.00003458044],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003146171,"about_ca_system_score_gemma":0.0003661802,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003521106,"about_ca_topic_score_gemma":0.00003638823,"domain_scores_codex":[0.9975982,0.0001251507,0.0007484585,0.0005999343,0.0005185544,0.0004096902],"domain_scores_gemma":[0.9985376,0.0006293395,0.0001338992,0.0002793504,0.00007580871,0.0003440244],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9723349,0.000314465,0.0003160459,0.003077222,0.001233907,0.00002293752,0.0006557233,0.00007354927,0.001442541,0.0008080227,0.01572397,0.003996683],"study_design_scores_gemma":[0.952919,0.0009378141,0.00252049,0.001965806,0.003964838,0.0000182451,0.00007323479,0.01468519,0.0009439322,0.0002088717,0.02137095,0.0003916036],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8856318,0.09475259,0.0005109198,0.003675422,0.002654473,0.008112608,0.002043646,0.0001011013,0.002517409],"genre_scores_gemma":[0.9839169,0.002215012,0.000197224,0.0004492126,0.00137894,0.0009721011,0.0002100449,0.00008345625,0.01057704],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09828514,"threshold_uncertainty_score":0.9999301,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01490438308467137,"score_gpt":0.3307358708547637,"score_spread":0.3158314877700923,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}